Obesity and metabolic comorbidity in bipolar disorder: do patients on lithium comprise a subgroup? A naturalistic study

Abstract Background Bipolar disorders (BD) are associated with increased prevalence of obesity and metabolic syndrome (MetS). Nevertheless, there is a wide range in prevalence estimates, with little known about the contributions of pharmacotherapy. It has been suggested that lithium might have a mor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jake Prillo, Jocelyn Fotso Soh, Haley Park, Serge Beaulieu, Outi Linnaranta, Soham Rej
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Obesity Metabolic syndrome lithium Insulin resistance Bipolar disorder Psychiatry RC435-571
Acceso en línea:	https://doaj.org/article/57547d95c0e545e3939bdafef525c683
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:57547d95c0e545e3939bdafef525c683
record_format	dspace
spelling	oai:doaj.org-article:57547d95c0e545e3939bdafef525c6832021-11-14T12:08:36ZObesity and metabolic comorbidity in bipolar disorder: do patients on lithium comprise a subgroup? A naturalistic study10.1186/s12888-021-03572-w1471-244Xhttps://doaj.org/article/57547d95c0e545e3939bdafef525c6832021-11-01T00:00:00Zhttps://doi.org/10.1186/s12888-021-03572-whttps://doaj.org/toc/1471-244XAbstract Background Bipolar disorders (BD) are associated with increased prevalence of obesity and metabolic syndrome (MetS). Nevertheless, there is a wide range in prevalence estimates, with little known about the contributions of pharmacotherapy. It has been suggested that lithium might have a more favorable metabolic profile. We hypothesized that lithium use is associated with less increased body mass index (BMI), MetS, and type II diabetes, when compared with non-lithium users (those on anticonvulsants, second-generation antipsychotics). Methods Cross-sectional study of 129 patients aged 18–85 with bipolar disorder, followed at tertiary care clinics in Montreal. Patients using lithium were compared with those not on lithium, for body mass index and metabolic syndrome. Results The prevalence of obesity and metabolic syndrome in the sample of lithium-using patients with BD was 42.4 and 35.7% respectively, with an average BMI of 29.10 (+/− 6.70). Lithium and non-lithium groups did not differ in BMI or prevalence of MetS. However, compared to the non-lithium group, lithium users had lower hemoglobin A1C (5.24 +/− 0.53 versus 6.01 +/− 1.83, U = 753.5, p = 0.006) and lower triglycerides (1.46 +/− 0.88 versus 2.01 +/− 1.25, U = 947, p = 0.020). Conclusions There is a high prevalence of obesity and metabolic syndrome among patients with bipolar disorder. However, this did not appear to be associated with lithium use, when compared to those not on lithium. The lithium subgroup was also associated with lower prevalence of type II diabetes. Future prospective and intervention studies with larger sample sizes are necessary to further explore the association between lithium and insulin resistance, as well as its underlying mechanisms.Jake PrilloJocelyn Fotso SohHaley ParkSerge BeaulieuOuti LinnarantaSoham RejBMCarticleObesityMetabolic syndromelithiumInsulin resistanceBipolar disorderPsychiatryRC435-571ENBMC Psychiatry, Vol 21, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Obesity Metabolic syndrome lithium Insulin resistance Bipolar disorder Psychiatry RC435-571
spellingShingle	Obesity Metabolic syndrome lithium Insulin resistance Bipolar disorder Psychiatry RC435-571 Jake Prillo Jocelyn Fotso Soh Haley Park Serge Beaulieu Outi Linnaranta Soham Rej Obesity and metabolic comorbidity in bipolar disorder: do patients on lithium comprise a subgroup? A naturalistic study
description	Abstract Background Bipolar disorders (BD) are associated with increased prevalence of obesity and metabolic syndrome (MetS). Nevertheless, there is a wide range in prevalence estimates, with little known about the contributions of pharmacotherapy. It has been suggested that lithium might have a more favorable metabolic profile. We hypothesized that lithium use is associated with less increased body mass index (BMI), MetS, and type II diabetes, when compared with non-lithium users (those on anticonvulsants, second-generation antipsychotics). Methods Cross-sectional study of 129 patients aged 18–85 with bipolar disorder, followed at tertiary care clinics in Montreal. Patients using lithium were compared with those not on lithium, for body mass index and metabolic syndrome. Results The prevalence of obesity and metabolic syndrome in the sample of lithium-using patients with BD was 42.4 and 35.7% respectively, with an average BMI of 29.10 (+/− 6.70). Lithium and non-lithium groups did not differ in BMI or prevalence of MetS. However, compared to the non-lithium group, lithium users had lower hemoglobin A1C (5.24 +/− 0.53 versus 6.01 +/− 1.83, U = 753.5, p = 0.006) and lower triglycerides (1.46 +/− 0.88 versus 2.01 +/− 1.25, U = 947, p = 0.020). Conclusions There is a high prevalence of obesity and metabolic syndrome among patients with bipolar disorder. However, this did not appear to be associated with lithium use, when compared to those not on lithium. The lithium subgroup was also associated with lower prevalence of type II diabetes. Future prospective and intervention studies with larger sample sizes are necessary to further explore the association between lithium and insulin resistance, as well as its underlying mechanisms.
format	article
author	Jake Prillo Jocelyn Fotso Soh Haley Park Serge Beaulieu Outi Linnaranta Soham Rej
author_facet	Jake Prillo Jocelyn Fotso Soh Haley Park Serge Beaulieu Outi Linnaranta Soham Rej
author_sort	Jake Prillo
title	Obesity and metabolic comorbidity in bipolar disorder: do patients on lithium comprise a subgroup? A naturalistic study
title_short	Obesity and metabolic comorbidity in bipolar disorder: do patients on lithium comprise a subgroup? A naturalistic study
title_full	Obesity and metabolic comorbidity in bipolar disorder: do patients on lithium comprise a subgroup? A naturalistic study
title_fullStr	Obesity and metabolic comorbidity in bipolar disorder: do patients on lithium comprise a subgroup? A naturalistic study
title_full_unstemmed	Obesity and metabolic comorbidity in bipolar disorder: do patients on lithium comprise a subgroup? A naturalistic study
title_sort	obesity and metabolic comorbidity in bipolar disorder: do patients on lithium comprise a subgroup? a naturalistic study
publisher	BMC
publishDate	2021
url	https://doaj.org/article/57547d95c0e545e3939bdafef525c683
work_keys_str_mv	AT jakeprillo obesityandmetaboliccomorbidityinbipolardisorderdopatientsonlithiumcompriseasubgroupanaturalisticstudy AT jocelynfotsosoh obesityandmetaboliccomorbidityinbipolardisorderdopatientsonlithiumcompriseasubgroupanaturalisticstudy AT haleypark obesityandmetaboliccomorbidityinbipolardisorderdopatientsonlithiumcompriseasubgroupanaturalisticstudy AT sergebeaulieu obesityandmetaboliccomorbidityinbipolardisorderdopatientsonlithiumcompriseasubgroupanaturalisticstudy AT outilinnaranta obesityandmetaboliccomorbidityinbipolardisorderdopatientsonlithiumcompriseasubgroupanaturalisticstudy AT sohamrej obesityandmetaboliccomorbidityinbipolardisorderdopatientsonlithiumcompriseasubgroupanaturalisticstudy
_version_	1718429403077148672

Obesity and metabolic comorbidity in bipolar disorder: do patients on lithium comprise a subgroup? A naturalistic study

Ejemplares similares